Home/Pipeline/AAV + Augmenter CFTR Gene Therapy

AAV + Augmenter CFTR Gene Therapy

Cystic Fibrosis

Pre-clinicalActive

Key Facts

Indication

Cystic Fibrosis

Phase

Pre-clinical

Status

Active

Company

Spirovant Sciences

About Spirovant Sciences

Spirovant Sciences is a private, clinical-stage biotechnology company pioneering gene therapies for cystic fibrosis and other genetic lung diseases. Its core technology is an integrated AAV + Augmenter platform designed to achieve high, durable expression of therapeutic genes like CFTR in airway cells. The company, led by an experienced team and backed by strategic acquisitions and foundation support, is advancing a lead CF program toward the clinic with the goal of providing a one-time curative treatment.

View full company profile

Therapeutic Areas

Cystic Fibrosis Respiratory Diseases

Other Cystic Fibrosis Drugs

Drug	Company	Phase	Status
CB-280	Calithera Biosciences	Preclinical/Phase 1	Discontinued
Ensifentrine	Verona Pharma	Phase 2	Under MSD
ALTA Drug Series	Alteron Therapeutics	Preclinical	Research
ColiFin®	Spexis	Marketed (EU)	Active
Cystic fibrosis (CRISPR)	GeneToBe	Discovery	Active
Cystic fibrosis (undisclosed)	GeneToBe	Early Discovery	Active
SM001 (alidornase/Tigerase)	SarcoMed USA	Research	Active
Targeted Lung Delivery	Nanite	Pre-clinical	Active
CFTR 100+ Panel	Agena Bioscience	Commercial	Active
RIG-301 CFTR	RIGImmune	Pre-clinical	Active
CBN-101	Carbon Biosciences	Preclinical	Active
RESP® Biosensor Evaluation (with Rutgers Health)	Strados Labs	Research Study	Active